US Biopharma In-Licenses 3 New Assets
Research Report
AI Cancer Discovery Shows Breakthrough in Brain-Targeting Treatment
Cleantech Co. Advances Antimicrobial Wound Care Breakthrough
Biopharma's New MASH Drug Has Two MOAs
Research Report
Life Sciences Co. Reports Strong Survival Data
Research Report
Therapeutics Company Advances Gene Therapy Breakthrough
Research Report
Biotech Firm Uncovers Breakthrough Gene Therapy in New York
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease
Research Report
Lexeo Therapeutics Inc. (LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases. Healthcare Tech Firm Finds Big U.S. Opportunity
Healthcare data firm OneMedNet Corporation (Nasdaq: ONMD) partners with Palantir Technologies Inc. (PLTR:NASDAQ) to analyze over 5 billion claims and 131 million exams, unlocking a possible massive U.S. breakthrough in AI-driven research.New Drug for Duchenne Muscular Dystrophy Nears Potential Approval
Research Report
Capricor Therapeutics Inc. (CAPR:NASDAQ) could receive a PDUFA date for its cell therapy as early as spring 2026 if it follows the FDA-outlined path forward, noted an Alliance Global Partners report. Clean Tech Co.'s 'Forever Chemical' Solution Is a PFAS Breakthrough
Clean technology company BioLargo Inc. (BLGO:OTCQX) announced compelling new findings about its proprietary Aqueous Electrostatic Concentration (AEC) "forever chemicals" solution. Read to discover why one expert thinks the breakthrough is important to the company's future.Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy
Capricor Therapeutics Inc. (CAPR:NASDAQ) reached agreement with the FDA to include HOPE-3 trial data in its BLA for Deramiocel, its cell therapy for Duchenne muscular dystrophy. With topline results due in Q4, learn how the company is advancing one of the few late-stage programs in this high-need rare disease space.Biotech Battles FDA, Target Price Shows Potential 90% Gains
Research Report
Capricor Therapeutics Inc. (CAPR:NASDAQ) has recently been involved in a "tug-of-war with the FDA." Read on to see why one Roth analyst still rates this stock as a Buy. Pharma's Flu Drug Could Be Worth Billions, Analyst Says
Research Report
Cidara Therapeutics Inc. (CDTX:NASDAQ) shares the minutes from an important meeting with the FDA, and the overall feedback was encouraging. Find out what one analyst predicts that will mean for Phase III development. Biotech Discovers Breakthrough DMD Therapy Opportunity
Research Report
Capricor Therapeutics Inc. (CAPR:NASDAQ) recently announced a favorable regulatory update, according to a research note from Oppenheimer & Co Inc. Seeking Formulation of New Drug, Biopharma Co. Signs LOI
Research Report
Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report. 
Streetwise Key Charts
